Unicycive Therapeutics, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request refers to 2023 Q4, this filing reports full-year results; it does not provide a clear standalone fourth-quarter financial summary. The company is a development-stage biotechnology business with no product sales to date. Its lead programs are Oxylanthanum Carbonate (OLC) for hyperphosphatemia in dialysis patients with chronic kidney disease and UNI-494 for acute kidney injury.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Licensing revenue | $0.675 million | $0.951 million |
| Research and development expense | $12.902 million | $12.436 million |
| General and administrative expense | $8.547 million | $6.567 million |
| Total operating expenses | $21.449 million | $19.003 million |
| Loss from operations | $(20.774) million | $(18.052) million |
| Net loss | $(30.544) million | $(18.058) million |
| Net loss attributable to common stockholders | $(31.411) million | $(18.058) million |
| Net cash used in operating activities | $(18.283) million | $(15.651) million |
| Cash at year-end | $9.701 million | $0.455 million |
- Revenue was licensing revenue, not product revenue. The 2023 amount primarily reflects the upfront payment from the South Korea license; no product revenue had been generated.
- At December 31, 2023, current assets were $13.399 million and current liabilities were $17.534 million, including a $13.134 million warrant liability. Total liabilities were $18.000 million; stockholders’ deficit was $3.809 million.
- Management reported no conventional borrowings in the presented balance sheet. Lease liabilities totaled about $0.793 million, including $0.327 million current. Cash and cash equivalents were the principal reported liquidity resource.
- There is no meaningful product gross margin to report because the company had no product sales.
Material changes versus 2022
- Licensing revenue fell 29%, from $0.951 million to $0.675 million, reflecting a smaller upfront payment from Lotus than the prior-year Lee’s Pharmaceutical payment.
- Operating expenses increased 13%. R&D rose 4%, mainly from higher labor and stock-based compensation, partly offset by lower drug-development costs. G&A rose 30%, principally from professional and consulting fees, hiring, and other operating costs.
- Net loss widened by $12.486 million. A $10.303 million noncash loss from the fair-value remeasurement of warrants was the principal unusual factor; the company also recorded $0.615 million of interest income. A $0.867 million deemed dividend on Series A-1 preferred stock increased the loss attributable to common stockholders beyond net loss.
- Operating cash use increased by $2.632 million. Financing activities provided $27.541 million in 2023, primarily from the March private placement; year-end cash increased by $9.246 million.
- Common shares outstanding increased from 15.232 million at year-end 2022 to 34.756 million at year-end 2023, following conversion of Series A-1 preferred stock. The filing also reports 160.958 million underlying shares for preferred-stock warrants and 10.302 million outstanding stock options at year-end, creating substantial potential dilution.
Outlook, milestones, risks, and unusual items
- OLC: The FDA required a tolerability study in dialysis patients before NDA submission. The company initiated the study in December 2023, expected topline data by the end of Q2 2024, and planned to submit an NDA soon afterward. These are forward-looking plans, not completed milestones.
- UNI-494: The Phase 1 healthy-volunteer study was underway in the UK; Part 1 was complete and Part 2 was ongoing. Completion was expected in the second half of 2024, with an FDA IND submission for a Phase 2 DGF study planned for Q4 2024. FDA granted orphan drug designation in February 2024.
- Funding: After year-end, the company issued $50 million of Series B convertible preferred stock in a March 2024 private placement, initially convertible at $1.00 per share, subject to adjustment. Management said year-end cash plus this financing was expected to fund operating needs for at least 12 months from the filing date and that substantial doubt about continuing operations was not present. The company nevertheless expects to need substantial additional capital.
- Financing and dilution: The March 2023 financing included warrants tied to OLC FDA approval, TDAPA approval, and commercial sales. Their year-end fair value was $13.134 million, and the $10.303 million 2023 remeasurement loss affected earnings but was noncash. Future warrant exercises and convertible preferred-stock conversion may dilute existing holders.
- Commercial and regulatory uncertainties: OLC and UNI-494 remain investigational. Approval, study results, launch timing, manufacturing readiness, reimbursement, dialysis-provider formulary access, competition, and the company’s ability to build commercial capabilities are material uncertainties. The anticipated Medicare TDAPA treatment and related pricing benefits are not assured.
- Other commitments: Under the Shilpa Medicare supply arrangement, payments totaling up to $10 million are contingent on FDA approval, commercial revenue reaching the specified threshold, and continued supply. The company also disclosed potential OLC milestone payments to Altair and royalties or sublicense-sharing obligations under its licenses.
- Controls and legal matters: Management identified a material weakness in internal control over financial reporting, citing insufficient accounting staffing and expertise, and expected remediation by the end of 2024 at additional cost. The auditors did not attest to internal-control effectiveness. The financial statements received an unqualified audit opinion. The company reported no pending legal proceedings it believed would have a material adverse effect. Nasdaq listing deficiencies identified in September 2023 were reported as resolved in February 2024.
Important facts for investors to verify
- Whether the OLC dialysis-patient study met its endpoints, when results were released, and whether the FDA accepted an NDA.
- UNI-494 Phase 1 completion, safety and tolerability findings, and progress toward the planned Phase 2 IND.
- Cash burn and liquidity after the March 2024 financing, including the Series B conversion terms, warrant exercise conditions, and resulting fully diluted share count.
- CMS decisions and timing for TDAPA eligibility, reimbursement coding, and eventual inclusion of phosphate-lowering drugs in the dialysis bundle.
- Progress in remediating the internal-control material weakness and any further disclosures about accounting controls or reporting reliability.